Embelin inhibits proliferation, induces apoptosis and alters gene expression profiles in breast cancer cells

作者：Shah Priyank; Djisam Ransford; Damulira Hamidah; Aganze Alice; Danquah Michael^*

来源：Pharmacological Reports, 2016, 68(3): 638-644.

DOI：10.1016/j.pharep.2016.01.004

• Embelin
• Breast cancer
• Gene expression profiling
• RT2 Profiler PCR Array
• Apoptosis

Purpose: To investigate effect of embelin on proliferation, apoptosis and gene expression profile changes in breast cancer cells.
Methods: Cell viability was determined by WIT assay and apoptosis assayed using flow cytometry. Differential expression of 84 genes commonly involved in breast cancer carcinogenesis was assessed by real-time PCR using the Human Breast Cancer RT2 Profiler PCR Array.
Results: MCF-7 and MDA-MB-231 cells were treated with embelin (0-25 mu M) for 24 and 96 h. Embelin exhibited time and dose dependence in both cell lines and was more potent in inhibiting MDA-MB-231 cell proliferation compared to MCF-7 cells. IC50 for embelin in MDA-MB-231 cells was similar to 4.45 M and 3.28 mu M at 24 h and 96 h, respectively. In contrast, IC50 for embelin in MCF-7 cells was 6.04,M and 4.51 mu M at 24 h and 96 h, respectively. Embelin (50 M) induced apoptosis and activated caspase 3 activity in both cell lines when exposed for 72 h. Treatment of MDA-MB-231 cells with embelin (10 mu M) for 24 h resulted in significant differential expression of 27 genes commonly involved in breast cancer carcinogenesis.
Conclusions: Our findings show that embelin inhibits cell proliferation, induces apoptosis and alters expression of breast cancer focused genes in MCF-7 and MDA-MB-231 cells. Based on RT2-PCR array analysis, embelin down-regulated expression of pivotal oncogenes. This knowledge could be beneficial in the de velopment of effective embelin-based therapies for treating breast cancer. Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.

• 出版日期2016